Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 19/20 | 0.45 |
| ▸ | CA2 | P00918 | 19/20 | 0.45 |
| ▸ | CA12 | O43570 | 5/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.45 |
| ▸ | CA4 | P22748 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9750004 | 1.00 | CA1 (0.45) | CA1CA2CA12CA9CA4 | |
| SCHEMBL21723688 | 0.86 | CA1 (0.45) | CA1CA2CA12CA9CA4 | |
| SCHEMBL5257610 | 0.84 | TGM2 (0.42) | CA1CA2CA12CA9CA4 | |
| SCHEMBL7598191 | 0.81 | SLC7A5 (0.44) | CA1CA2CA12CA9CA4 | |
| SCHEMBL7596061 | 0.81 | CYP1A2 (0.43) | CA1CA2 | |
| SCHEMBL29588115 | 0.81 | CYP1A2 (0.43) | CA1CA2 | |
| SCHEMBL9435308 | 0.80 | TDP1 (0.39) | CA1CA2CA12CA9CA4 | |
| SCHEMBL5252487 | 0.80 | TDP1 (0.39) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2538468 | 0.79 | KMT2A (0.43) | CA1CA2CA12CA9CA4 | |
| SCHEMBL7170464 | 0.79 | KMT2A (0.43) | CA1CA2CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0327365-B1 | Improvements in or relating to modified haptens useful as imaging and therapeutic agents | HYBRITECH INC (US) | 1994-06-15 | — | — | EP | claimed |
| EP-0327365-A2 | Improvements in or relating to modified haptens useful as imaging and therapeutic agents | HYBRITECH INCORPORATED (US) | 1989-08-09 | — | — | EP | claimed |
| US-12618837-B2 | Method of identifying pro-inflammatory dendritic cells | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2026-05-05 | — | — | US | disclosed |
| US-12414990-B2 | Use of HLA-A*11:01-restricted hepatitis B virus (HBV) peptides for identifying HBV-specific CD8+ T cells | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-09-16 | — | — | US | disclosed |
| US-12111313-B2 | Chelator-coated field effect transistor and devices and methods using same | Autonomous Medical Devices Inc. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240201192-A1 | FOLR2+ MACROPHAGES AND ANTI-TUMOR IMMUNITY | INSTITUT CURIE (FR) | 2024-06-20 | — | — | US | disclosed |
| EP-4323770-A1 | FOLR2+ MACROPHAGES AND ANTI-TUMOR IMMUNITY | Institut Curie (FR) | 2024-02-21 | — | — | EP | disclosed |
| EP-3507601-B1 | METHODS FOR THE IDENTIFICATION, TARGETING AND ISOLATION OF HUMAN DENDRITIC CELL (DC) PRECURSORS \"PRE-DC\ | AGENCY SCIENCE TECH & RES (SG) | 2023-08-16 | — | — | EP | disclosed |
| US-20230184762-A1 | Method of Identifying Pro-Inflammatory Dendritic Cells | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-15 | — | — | US | disclosed |
| CN-109906381-B | Methods of identifying, targeting and isolating human Dendritic Cell (DC) precursors, 'pre-DCs', and uses thereof | 新加坡科技研究局 | 2023-03-31 | — | — | CN | disclosed |
| US-20230087348-A1 | USE OF HLA-A*11:01-RESTRICTED HEPATITIS B VIRUS (HBV) PEPTIDES FOR IDENTIFYING HBV-SPECIFIC CD8+ T CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-03-23 | — | — | US | disclosed |
| CN-114341644-A | Methods for identifying proinflammatory dendritic cells | 新加坡科技研究局 | 2022-04-12 | — | — | CN | disclosed |
| US-20140073528-A1 | METHODS OF DEPLETING A TARGET MOLECULE IN A SAMPLE AND KITS FOR PRACTICING THE SAME | CLONTECH LABORATORIES, INC. | 2014-03-13 | — | — | US | disclosed |
| EP-0327365-B1 | Improvements in or relating to modified haptens useful as imaging and therapeutic agents | HYBRITECH INC (US) | 1994-06-15 | — | — | EP | disclosed |
| WO-1993002652-A2 | MODIFIED HAPTENS USEFUL AS IMAGING AND THERAPEUTIC AGENTS | HYBRITECH INCORPORATED (US) | 1993-02-18 | — | — | WO | disclosed |
| EP-0251494-B1 | THERAPEUTIC OR RADIODIAGNOSTIC COMPOUND | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1992-09-30 | — | — | EP | disclosed |
| US-4863713-A | DIAGNOSIS OF TUMORS | THE BOARD OF TRUSTEES OF LELAND STANFORD JR. UNIV. (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0327365-A2 | Improvements in or relating to modified haptens useful as imaging and therapeutic agents | HYBRITECH INCORPORATED (US) | 1989-08-09 | — | — | EP | disclosed |
| US-4758421-A | Bleomycin conjugates and method | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0251494-A2 | Therapeutic or radiodiagnostic compound | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618837-B2 | Method of identifying pro-inflammatory dendritic cells | CD14, CD58, CD69 | CA1 3214/4885CA2 4616/4885CA12 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.